• Oncology
  • Current

Maverick Therapeutics, Inc. is a preclinical stage biotech company founded by MPM that is developing a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism.  Critical to the opportunity, the antibodies are designed to extend the therapeutic index via their selective activation in the tumor microenvironment.